Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 15.00
-0.12 (-0.79%)
Jul 24, 2026, 5:00 PM CET
Ryvu Therapeutics Cash Flow Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -88.6 | -101.23 | -111.44 | -92.11 | -83.78 | -79.08 |
Depreciation & Amortization | 9.58 | 9.86 | 10.5 | 10.97 | 12.9 | 12.56 |
Stock-Based Compensation | 1.91 | 2.77 | 4.14 | 8.31 | 22.18 | 23 |
Other Adjustments | 11.81 | 16.34 | -12.09 | 2.55 | 8.81 | -6.15 |
Change in Receivables | 8.15 | 15.68 | -2.94 | -15.91 | -5.56 | -3.79 |
Changes in Inventories | - | -0.13 | 0.91 | -0.36 | 0.2 | -0.28 |
Changes in Accounts Payable | -34.13 | -59.2 | -9.75 | 9.91 | -0.5 | 9.8 |
Changes in Income Taxes Payable | - | - | - | - | -5.46 | 0 |
Changes in Unearned Revenue | -4.54 | -0.95 | -6.89 | 5.09 | 70.43 | -13.91 |
Changes in Other Operating Activities | 3.19 | 2.77 | -1.92 | -13 | 2.11 | -1.03 |
Operating Cash Flow | -92.76 | -114.1 | -129.48 | -84.55 | 21.32 | -58.89 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -7.41 | -7.47 | -5.9 | -8.58 | -1.52 | -11.98 |
Purchases of Investments | 0.3 | 20.82 | - | -192.61 | -0.53 | -4.99 |
Proceeds from Sale of Investments | - | - | - | - | 4.99 | 24.97 |
Other Investing Activities | 2.62 | 3.82 | 143.07 | 5.65 | -2.26 | 0.06 |
Investing Cash Flow | -4.5 | 17.16 | 137.17 | -195.54 | 0.69 | 8.06 |
Long-Term Debt Issued | -2.57 | -2.54 | 94.49 | 0.13 | 1.15 | 1.02 |
Long-Term Debt Repaid | -0.37 | -0.52 | -0.28 | -1.79 | -2.51 | -3.21 |
Net Long-Term Debt Issued (Repaid) | -2.93 | -3.05 | 94.22 | -1.66 | -1.37 | -2.19 |
Issuance of Common Stock | - | - | - | 250.28 | 0 | 0.24 |
Net Common Stock Issued (Repurchased) | - | - | - | 250.28 | 0 | 0.24 |
Other Financing Activities | - | 0 | -0.01 | -7.79 | -1.09 | -0.2 |
Financing Cash Flow | -2.93 | -3.05 | 94.21 | 240.83 | -2.46 | -2.15 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -1.87 | -0.48 | 0.24 | -4.72 | -0.87 | 0 |
Net Cash Flow | -100.19 | -99.99 | 101.9 | -39.26 | 19.55 | -52.98 |
Free Cash Flow | -100.17 | -121.57 | -135.38 | -93.13 | 19.8 | -70.87 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -113.30% | -138.57% | -132.67% | -136.97% | 28.09% | -196.13% |
Free Cash Flow Per Share | -4.33 | -5.26 | -5.86 | -4.07 | 1.08 | -3.86 |
Levered Free Cash Flow | -124.84 | -159.41 | -30.27 | -89.75 | -6.99 | -86.12 |
Unlevered Free Cash Flow | -115.38 | -162.83 | -135.47 | -96.93 | -4.81 | -83.56 |